Paper Details

  1. Home
  2. Paper Details

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Author: AustinDaren J, Bar-OrAmit, DerosierFrederick J, GroveRichard A, KavanaghSarah T, LewisEric W, LopezMonica C, MillerAaron E, SorensenPer S, TolsonJerry M, VanMeterSusan A

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ofatumumab, an anti-CD20 monoclonal antibody, is an effective treatment for relapsing forms of multiple sclerosis (RMS). All subcutaneous ofatumumab doses demonstrated efficacy in reducing the number of new MRI gadolinium-enhancing lesions. The safety profile was consistent with existing ofatumumab data and no serious adverse events were reported.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS). METHODS: Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957306/

データ提供：米国国立医学図書館（NLM）

Ofatumumab: A Promising New Treatment for Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting multiple sclerosis (RMS) is a chronic autoimmune disease that affects the central nervous system. This study investigates the efficacy and safety of ofatumumab, an anti-CD20 monoclonal antibody, in patients with RMS. The researchers conducted a phase 2b double-blind study, meaning neither the patients nor the researchers knew who was receiving the active drug and who was receiving the placebo. The study found that ofatumumab effectively reduced the number of new brain lesions in patients with RMS, with a more robust effect observed at higher doses. The study also found that ofatumumab was generally safe and well-tolerated, with a safety profile consistent with previous studies. This research provides valuable evidence supporting the use of ofatumumab as a promising new treatment for RMS.

Ofatumumab: A Potential Game-Changer for RMS Treatment

The study's findings suggest that ofatumumab could be a significant advancement in RMS treatment. Its efficacy in reducing brain lesions and its favorable safety profile make it a compelling option for patients with RMS.

Navigating the Treatment Landscape for RMS

This research highlights the ongoing efforts to develop new and effective treatments for RMS. The development of ofatumumab represents a significant step forward in the fight against this challenging disease. It's important for healthcare providers and patients to stay informed about the latest treatment options and to work together to achieve optimal treatment outcomes.

Dr. Camel's Conclusion

This study offers a hopeful outlook for the treatment of RMS. The development of ofatumumab provides a new weapon in the fight against this debilitating disease. The research highlights the promise of targeted therapies and the ongoing commitment to improving the lives of patients with RMS.

Date :
  1. Date Completed 2019-08-07
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

29695594

DOI: Digital Object Identifier

PMC5957306

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.